Follicular Lymphoma


Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma (March 22, 2013)

Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 7, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients... Continue Reading

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients... Continue Reading

Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results... Continue Reading

Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (January 11, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) produces statistically and clinically significant higher overall response rates and complete response rates compared to Rituxan® (rituximab)... Continue Reading

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma (January 10, 2013)

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with... Continue Reading

Advanced Directives (September 25, 2012)

Living Wills Every competent adult has, in most cases, the freedom to accept or refuse medical treatment. When you are well, you can talk with your physician and family and make your wishes known. However,... Continue Reading

Men, Fertility, and Cancer (July 6, 2012)

Men who confront a cancer diagnosis before beginning or completing their families may have many questions about how cancer treatment will affect their ability to have children in the future. The good news... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according... Continue Reading

CancerConnect Live Web Chat with Dr. Barrie Cassileth from Memorial Sloan-Kettering Cancer Center on Complementary Cancer Therapies on Thursday, November 17th at 6PM EST (November 17, 2011)

Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service; Laurance S. Rockefeller Chair Integrative Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), click here for Dr.... Continue Reading

Chemotherapy During Pregnancy Not Linked with Developmental Problems in Kids (October 4, 2011)

According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart... Continue Reading

Clinical Trial Participation Is Inadequate (August 31, 2011)

A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups.... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS